Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Irinotecan Dosing in mCRC (IriGen)
NCT01963182Phase 2Completed
- Sponsor
- Centre Jean Perrin
- Start
- Oct 2013
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in colorectal cancer (CRC), sponsored by Centre Jean Perrin. Primary endpoints: Severe toxicity (according to NCI-CTC cotation) at 7 months and Response with adapted dose of irinotecan at 7 months. Started Oct 2013; status: completed.
02
Drugs
irinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01963182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963182.